Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome

Sponsor
Peking University People's Hospital
Study ID
NCT05087589
Phase
PHASE2
Status
Unknown

Conditions

  • Primary Sjögren's Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tofacitinib — DRUG
    Tofacitinib 5mg was taken orally twice a day for 6 months

Study Details

This study aims to explore the clinical and immunological efficacy of tofacitinib on primary Sjögren's Syndrome

Key Dates

Start date
Nov 20, 2021
Status verified
Oct 2021
Primary completion
Jan 1, 2023
Completion
Oct 1, 2023

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: tofacitinib
    Tofacitinib 5mg was taken orally twice a day for 6 months

Primary Outcome Measure

Immunological Responses [ Time Frame: week 24 ]

Central Contacts

Related Studies